A hollow drug-loaded nanozyme, preparation method and anti-tumor drug
The preparation of idle drug-loaded nanoenzymes by silica template-assisted etching method solved the problem of GSH inhibiting ROS clearance in tumor cells, and achieved enhanced ROS generation and inhibiting ROS clearance in tumor cells, significantly improving chemokinetic therapy and anti-tumor efficacy.
Patent Information
- Application Number
- CN202311327781.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-10-13
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2043-10-13
AI Technical Summary
Overexpressed glutathione (GSH) in tumor cells inhibits the effect of reactive oxygen species (ROS)-based chemokinetic therapy. Existing metal nanoparticles are inefficient in ROS generation and removal, making it difficult to effectively induce oxidation of tumor cells. damage.
The hollow drug-loaded nanoenzyme was prepared by silica template-assisted etching method. By etching SiO2 in the nanoparticles wrapped in SiO2, the internal hollow MnO2 nanoparticles were formed, which enhanced ROS generation and inhibited ROS removal as an anti-anti- Carrier of tumor drugs to improve ROS levels in tumor cells.
It significantly enhanced the effect of chemokinetic therapy, improved the ROS level in tumor cells, enhanced the anti-tumor efficacy, and further improved the chemotherapy effect by loading cisplatin drugs.
Smart Images

Figure CN117383616B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine and nanomedicine, and specifically relates to a hollow drug-loaded nanozyme, a preparation method, and an anti-tumor drug containing the nanozyme and a preparation method thereof. Background Art
[0002] In recent years, cancer has gradually become a major disease that endangers human health and life, and its treatment has always been the focus of medical attention. However, the effects of ordinary treatment methods are not satisfactory, mainly because tumors are resistant to treatment methods.
[0003] Currently, much effort has been devoted to the development of reactive oxygen species (ROS)-based cancer therapeutic strategies, especially chemodynamic therapy (CDT), which exploits the endogenous H2O2 production-dependent Fenton reaction to convert inactive H2O2 into reactive oxygen species·OH, which are highly oxidatively active, to induce intracellular oxidative stress and lead to severe oxidative damage in tumor cells. Importantly, as an endogenous prodrug for tumor CDT, H2O2 is overproduced in cancer cells. Therefore, the accumulation of H2O2 in cancer cells has been used as a trigger for a variety of therapeutic approaches. To date, several iron-loaded nanoparticles have been used as CDT agents, as well as nanoparticles including Mn 2+ 、Co 2+ 、Mo 4+ and Cu + Some other metal ions including α-Hg and β-Hg also showed Fenton-like activity.
[0004] However, overexpressed glutathione (GSH) in tumor cells, as a ROS scavenger, has a potential inhibitory effect on the highly reactive ·OH generated by chemokinetic reagents, which is one of the most challenging obstacles for CDT.
[0005] Therefore, it is necessary to develop a Fenton-like drug-loaded metal nanoformulation that can enhance the generation of ROS while inhibiting the clearance of ROS and has better chemical kinetic efficiency than existing metal nanoparticles. Summary of the invention
[0006] In view of the problems existing in the prior art, the first purpose of the present invention is to provide a hollow drug-loaded nanozyme and a method for preparing the same. The present invention uses the method of "silicon dioxide template assisted etching" to etch the SiO2 in the nanoparticles of MnO2 wrapped SiO2 (recorded as SiO2@MnO2) to obtain hollow MnO2 nanoparticles, which are hollow drug-loaded nanozymes. It has been found through experiments that the hollow drug-loaded nanozymes of the present invention enhance the generation of ROS on the one hand and inhibit the removal of ROS on the other hand, and comprehensively achieve the effect of increasing the level of ROS in tumor cells, thereby enhancing the CDT effect, and are ideal carriers for preparing anti-tumor nanomedicines. The second purpose of the present invention is to provide an anti-tumor drug and a method for preparing the same. The hollow drug-loaded nanozyme disclosed in the present invention can also be used to load anti-tumor drugs, further enhancing the anti-tumor efficacy of nanoformulations combined with chemotherapy drugs.
[0007] Based on the above purpose, the technical solution adopted by the present invention is as follows:
[0008] In a first aspect, the present invention provides a hollow drug-loaded nanozyme, wherein the hollow drug-loaded nanozyme is a MnO2 nanoparticle with a hollow interior, and the particle size of the MnO2 nanoparticle is 170 to 230 nm.
[0009] The MnO2 nanoparticles provided by the present invention have a small particle size, which is conducive to the internalization of the nanoparticles into tumor cells. In addition, the MnO2 nanoparticles of the present invention show a narrow hydrodynamic size distribution and a small PDI value (0.255), indicating that the MnO2 nanoparticles of the present invention have a relatively high dispersibility in water.
[0010] In a second aspect, the present invention provides a method for preparing the hollow drug-loaded nanozyme, comprising the following steps:
[0011] S1: adding a manganese source to a SiO2 nanoparticle water suspension and dispersing the mixture uniformly to form a mixed solution, adding polyallylamine hydrochloride (PAH) to the mixed solution, and obtaining MnO2-coated SiO2 nanoparticles (denoted as SiO2@MnO2) through a light-protected reaction;
[0012] S2: etching and removing SiO2 in the MnO2-wrapped SiO2 nanoparticles (SiO2@MnO2) to obtain MnO2 nanoparticles with hollow interior.
[0013] Preferably, the polyallylamine hydrochloride is added to the mixed solution in the form of an aqueous solution thereof, and the concentration of the polyallylamine hydrochloride aqueous solution is 10-50M.
[0014] The present invention adopts adding polyallylamine hydrochloride (PAH) to the mixed solution of manganese source and SiO2 nanoparticles, PAH is positively charged in aqueous solution, and the amino group on PAH is connected to the negatively charged SiO2 surface. At the same time, PAH acts as a reducing agent to reduce KMnO4 to MnO2, so that MnO2 is wrapped on the SiO2 surface. The PAH added to the system not only realizes the coating of MnO2 on the surface of the silicon dioxide nanoparticles, but also improves the stability of the coating of MnO2 on the surface of the silicon dioxide nanoparticles. The reaction process adopts light-shielding treatment to avoid the influence of light on the reaction system and ensure the stability of the reactants and reaction products.
[0015] Preferably, in the above step S1, the manganese source is KMnO4 or MnSO4; and the SiO2 nanoparticles are prepared by hydrolyzing ethyl orthosilicate in ethanol via ammonia catalysis.
[0016] Preferably, in the above step S2, MnO2-wrapped SiO2 nanoparticles (SiO2@MnO2) are added to a Na2CO3 aqueous solution, and SiO2 in the nanoparticles SiO2@MnO2 is removed by etching reaction at 60°C to 85°C, and hollow MnO2 nanoparticles are obtained after etching, which are recorded as HMnO2. The particle size of the HMnO2 nanoparticles is 170 to 230 nm.
[0017] It is found through experiments that the internal drug loading rate of the hollow MnO2 nanoparticles prepared by the present invention can reach 60% to 70%.
[0018] Na2CO3 is a strong base and weak acid salt, has good water solubility, is easy to use, and is non-toxic and harmless.
[0019] Preferably, the molar concentration of the above-mentioned Na2CO3 aqueous solution is 0.5~4M.
[0020] Experiments have shown that when the molar concentration of the Na2CO3 aqueous solution is less than 0.5M, the etching degree is low, which reduces the effective utilization rate of the hollow nanoparticles. When the molar concentration of the Na2CO3 aqueous solution is greater than 4M, the high concentration solution is not conducive to the formation of hollow nanomaterials and reduces the dispersion stability of MnO2 nanoparticles.
[0021] In a third aspect, the present invention provides the use of the above-mentioned hollow drug-loaded nanozyme in the preparation of anti-tumor nanomedicines.
[0022] In a fourth aspect, the present invention provides an anti-tumor nanomedicine, which is prepared by loading cisplatin (CDDP) into the above-mentioned hollow drug-loaded nanozyme.
[0023] Preferably, the above tumors include ovarian cancer, prostate cancer, testicular cancer, lung cancer, nasopharyngeal carcinoma, esophageal cancer, malignant lymphoma, head and neck squamous cell carcinoma, thyroid cancer and osteosarcoma.
[0024] In a fifth aspect, the present invention provides a method for preparing the above-mentioned anti-tumor nanomedicine, comprising the following steps:
[0025] The hollow drug-loaded nanozyme is added into a cisplatin aqueous solution, and a nanodrug (denoted as HMnO2@CDDP) loaded with cisplatin is formed on MnO2 nanoparticles through a light-protected reaction, which is the anti-tumor nanodrug.
[0026] Through UV-vis detection and analysis of HMnO2, CDDP, and HMnO2@CDDP, the HMnO2@CDDP prepared by the present invention has a strong surface plasmon resonance absorption band at 260nm. After CDDP is loaded into HMnO2, the UV absorption of CDDP has a blue shift from 300nm to 260nm. The change in the absorption peak confirms the successful loading of CDDP on the nanoparticle HMnO2.
[0027] Preferably, the hollow drug-loaded nanozyme is dispersed in water to form a dispersion with a concentration of 1.0 to 5.0 mg / mL, and the dispersion is added to a cisplatin aqueous solution to form a mixed solution, wherein the concentration of the cisplatin aqueous solution is 0.1 to 0.5 mg / mL. In the mixed solution, the mass ratio of the hollow drug-loaded nanozyme to cisplatin is 0.2:1, and this ratio can ensure the maximization of the cisplatin loading amount.
[0028] Compared with the prior art, the present invention has the following beneficial effects:
[0029] (1) The hollow drug-loaded nanozyme provided by the present invention has a particle size of 170 to 230 nm and has good dispersion stability. It is easily internalized into tumor cells. While enhancing the generation of ROS, it depletes glutathione (GSH) in the tumor microenvironment, inhibits the scavenging effect of GSH on ROS, comprehensively improves the ROS level in the tumor microenvironment, and significantly enhances the CDT effect. The hollow drug-loaded nanozyme of the present invention is an ideal carrier for combined chemotherapeutic drug nanoformulations.
[0030] (2) The anti-tumor nanodrug provided by the present invention is a nanodrug HMnO2@CDDP loaded with CDDP on a hollow drug-loaded nanozyme. The anti-tumor nanodrug has both the characteristics of the hollow drug-loaded nanozyme to enhance the ROS level in the tumor microenvironment and the anti-tumor effect of CDDP. In addition, the nanodrug HMnO2@CDDP depletes GSH in cancer cells in the tumor microenvironment, thereby amplifying the DNA damage caused by the chemotherapy drug CDDP, enhancing the CDT effect, promoting the apoptosis of cancer cells, and enhancing the anti-tumor efficacy of the nanodrug HMnO2@CDDP. BRIEF DESCRIPTION OF THE DRAWINGS
[0031] Figure 1 This is a transmission electron microscope photo of the hollow drug-loaded nanozyme obtained in Example 1;
[0032] Figure 2 This is the particle size distribution diagram of the hollow drug-loaded nanozyme obtained in Example 1;
[0033] Figure 3 This is the UV-vis image of the cisplatin-loaded anti-tumor nanodrug (HMnO2@CDDP) obtained in Example 2;
[0034] Figure 4 It is a bar graph of intracellular GSH levels corresponding to different treatments;
[0035] Figure 5 CLSM images of cells treated with different nanoparticles and DCF in Example 3;
[0036] Figure 6 CLSM images of cells after being stained with different nanoparticles and fluorescently labeled antibodies in Example 3;
[0037] Figure 7 This is a fluorescence image of the distribution of anti-tumor nanodrug HMnO2@CDDP in animals. DETAILED DESCRIPTION
[0038] In order to better illustrate the purpose, technical scheme and advantages of the present invention, the present invention will be further described below in conjunction with specific embodiments. It should be understood by those skilled in the art that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention. The test methods used in the examples are conventional methods unless otherwise specified; the materials, reagents, etc. used can be obtained from commercial sources unless otherwise specified.
[0039] Example 1
[0040] This embodiment provides a method for preparing a hollow drug-loaded nanozyme based on a "silicon dioxide template-assisted etching" strategy. The specific preparation method includes the following steps:
[0041] S1: Preparation of SiO2 nanoparticles
[0042] 1 mL of tetraethyl orthosilicate (TEOS) was slowly added dropwise to 10 mL of deionized water containing 1.25 mL of EtOH and 0.32 mL of NH3·H2O (25%), and then stirred at 100-1500 r / min for 72 hours at room temperature. After the reaction was completed, the reactants were washed three times by centrifugation using EtOH and water (8000×g, 15 min), and the resulting precipitate was SiO2 nanoparticles, which were resuspended in deionized water and stored for later use.
[0043] S2: Preparation of SiO2@MnO2 nanoparticles
[0044] Take an aqueous solution containing 50 mg KMnO4 and add it to an aqueous suspension containing 6.5 mg SiO2 nanoparticles. After ultrasonic mixing, add it dropwise to a polyallylamine hydrochloride (PAH) aqueous solution (10-50 M). Stop adding when the reaction solution turns light yellow. Continue stirring for 24 hours in the dark to obtain MnO2-coated SiO2 nanoparticles, which are recorded as SiO2@MnO2. PAH is positively charged in aqueous solution, and the amino groups on PAH are connected to the negatively charged SiO2 surface. At the same time, PAH acts as a reducing agent to reduce KMnO4 to MnO2, so that MnO2 is wrapped on the SiO2 surface, and finally obtains MnO2-coated SiO2 nanoparticles (i.e., SiO2@MnO2 nanoparticles).
[0045] S3: Preparation of hollow MnO2 nanoparticles
[0046] Take 20mg of nanoparticles SiO2@MnO2 and add them to Na2CO3 (0.5-4M) aqueous solution, stir continuously at 60℃-85℃ for 12 hours to remove the silica template. After the reaction, the product is centrifuged and washed three times with deionized water (9000×g, 15min) to obtain hollow metal oxide HMnO2 with nanozyme activity, that is, MnO2 nanoparticles with hollow interior, that is, hollow drug-loaded nanozymes. The transmission electron microscope photo is shown in the figure. Figure 1 As shown, the particle size is 170-230 nm. The MnO2 nanoparticles prepared by the present invention have a smaller particle size, which is conducive to the internalization of the nanoparticles into tumor cells.
[0047] In addition, MnO2 nanoparticles show a narrow hydrodynamic size distribution, e.g. Figure 2 As shown, it has a smaller PDI value (0.255), indicating that the MnO2 nanoparticles of the present invention have relatively high dispersion stability in water.
[0048] Comparative Example 1
[0049] The difference between this comparative example and Example 1 is that PAH is not added in step S2 of this comparative example, and the rest of the unmentioned parts are the same as Example 1. It is found that the color of the reaction solution in this comparative example does not change, KMnO4 is not reduced, and the formation of nanoparticles of MnO2 coated on the surface of SiO2 is not observed.
[0050] Comparative Example 2
[0051] Referring to the method described in Example 1, the molar concentration of the Na2CO3 aqueous solution in step S3 is adjusted to 0.1-0.4M, which is less than 0.5M described in Example 1. Experiments have shown that when the molar concentration of the Na2CO3 aqueous solution is less than 0.5M, the degree of etching is low, thereby reducing the effective utilization rate of the hollow nanoparticles.
[0052] Referring to the method described in Example 1, the molar concentration of the Na2CO3 aqueous solution in step S3 is adjusted to 5-15M, which is greater than 4M described in Example 1. Experiments have shown that when the concentration of the Na2CO3 aqueous solution is higher than 4M, it is not conducive to the formation of hollow nanomaterials and reduces the dispersion stability of the nanoparticles.
[0053] Comparative Example 3
[0054] Referring to the method described in paragraph 0034 of the specification of the prior art (202211354253.X, Preparation and Application of Dopamine-encapsulated Hollow Mesoporous Manganese Dioxide Nano-drug Delivery System), the hollow manganese dioxide particles were prepared. The experimental method is as follows:
[0055] Disperse 10-50 mg KMnO4 in 10 mL ultrapure water, slowly drip into 10 mg SiO2 solution, magnetically stir for 5 minutes, ultrasonicate the reaction solution for 6 hours, and stir at room temperature for 18 hours; centrifuge the reaction solution, discard the supernatant, add ultrapure water to resuspend, centrifuge at 10000 rpm for 15 minutes, discard the supernatant, repeat this process 3 times, disperse the obtained SiO2@MnO2 nanoparticles in sodium carbonate aqueous solution, magnetically stir at 60°C for 12 hours to etch SiO2; centrifuge the etched reaction solution, discard the supernatant, wash with water 3 times, and obtain HMnO2. By comparison, it is found that compared with the prior art, the nanoparticles prepared by the method of the present invention are more uniform in size and have better dispersibility in aqueous solution. The polydispersity index (PDI) of HMnO2 prepared by the present invention is 0.255 ( Figure 2 ).
[0056] Comparative Example 4
[0057] The difference between this comparative example and Example 1 is that step S3 is different. In this comparative example, the nanoparticles SiO2@MnO2 prepared by the above step S2 are centrifuged at room temperature, and the precipitate obtained after centrifugation is washed with deionized water to obtain nanoparticles SiO2@MnO2. Compared with Example 1, the SiO2@MnO2 nanoparticles prepared in this comparative example are nanoparticles with solid interiors and have not been etched.
[0058] After washing, the drug content in the supernatant after centrifugation was measured, and the surface drug loading rate of the solid MnO2 nanoparticles was calculated to be only 10-20%. The solid nanoparticles greatly reduce the drug loading efficiency.
[0059] Comparative Example 5
[0060] The difference between this comparative example and Example 1 is that in this comparative example, NaOH aqueous solution (0.5-4M) is used to replace the Na2CO3 aqueous solution in step S3 of Example 1, and SiO2 in the nanoparticles SiO2@MnO2 is removed by etching reaction at 60°C-70°C, and MnO2 nanoparticles with hollow interiors can be obtained after etching. Since NaOH, which is also an alkali solution, is more corrosive, the stability of the hollow nanoparticles formed is reduced to a certain extent.
[0061] Comparative Example 6
[0062] The difference between this comparative example and Example 1 is that this comparative example replaces the Na2CO3 aqueous solution in step S3 of Example 1 with a CuSO4 aqueous solution (0.5-4M), and removes SiO2 in the nanoparticles SiO2@MnO2 by etching reaction at 65°C-85°C, and obtains MnO2 nanoparticles with hollow interior after etching. Since the CuSO4 aqueous solution has color, it has certain interference. Therefore, the present invention adopts the Na2CO3 aqueous solution as the SiO2 removal liquid, which has strong operability, low cost, simple reaction, mild preparation process conditions, clean and pollution-free reaction process, and high reaction efficiency.
[0063] Example 2
[0064] In this embodiment, the anti-tumor nanoparticles HMnO2@CDDP loaded with cisplatin are synthesized based on the MnO2 nanoparticles prepared in Example 1. The preparation method of the anti-tumor nanoparticles includes the following steps:
[0065] S1: Preparation of CDDP aqueous solution
[0066] 1.0 mg of cisplatin (CDDP) was weighed and added to 10.0 mL of PBS (pH=7.4), and heated in a 50° C. water bath to dissolve. During the process, a glass rod was used to stir to accelerate the dissolution, thereby obtaining a CDDP aqueous solution.
[0067] S2: Preparation of antitumor nanodrug (HMnO2@CDDP)
[0068] 200 μL of the hollow MnO2 nanoparticles (HMnO2) aqueous dispersion prepared in Example 1 was added to the CDDP aqueous solution. The concentration of the MnO2 nanoparticle aqueous dispersion was 1 mg / mL. A uniform vortexer was used to stir overnight in the dark to form a mixed solution. In the mixed solution, the mass ratio of the hollow drug-loaded nanozyme to cisplatin was 0.2:1. The obtained mixed solution was then centrifuged at 3500 rpm for 5 min. The obtained precipitate was the anti-tumor nanodrug (HMnO2@CDDP) loaded with cisplatin on HMnO2. Finally, the anti-tumor nanodrug HMnO2@CDDP was washed several times with PBS.
[0069] The results of UV-vis detection and analysis of HMnO2, CDDP, and HMnO2@CDDP are as follows: Figure 3 As shown, the HMnO2@CDDP prepared by the present invention has a strong surface plasmon resonance absorption band at 260nm. After CDDP is loaded into HMnO2, the UV absorption of CDDP has a blue shift from 300nm to 260nm. The change in the absorption peak confirms the successful loading of CDDP on the hollow nanoparticles HMnO2. The internal drug loading rate of the hollow MnO2 nanoparticles can reach 60% to 70%.
[0070] Example 3 Cell experiment
[0071] In this example, the hollow MnO2 nanoparticles (HMnO2) prepared in Example 1 and the anti-tumor nanodrug (HMnO2@CDDP) prepared in Example 2 were subjected to intracellular GSH depletion, reactive oxygen level detection, DNA damage analysis, and distribution analysis in animals through cell experiments. The specific experimental methods are as follows:
[0072] (1) Glutathione level detection
[0073] The cell lysates were quantitatively analyzed by Ellman's test as follows:
[0074] A549 cells were seeded in 96-well plates at a density of 10 4 / well and cultured overnight at 37°C. Afterwards, different concentrations (2.5 μg mL -1 , 5 μg mL -1 , 10 μg mL -1 ) and different formulations (CDDP, HMnO2, HMnO2@CDDP) were added to 96-well plates and cultured for 12 hours. Next, the drug medium was discarded, 10% TritonX-100 cell lysis buffer was added, lysed for 5 minutes, centrifuged at 4000 rpm for 5 minutes, the supernatant was absorbed, and the GSH levels of different groups were detected using a GSH detection kit according to the instructions.
[0075] The depletion of GSH caused by HMnO2@CDDP was confirmed. HMnO2@CDDP was able to deplete intracellular GSH in a concentration-dependent manner. Compared with A549 cells without any treatment (Control group), the intracellular GSH level decreased by 30% after treatment with 10μg / ml HMnO2@CDDP. Figure 4 It was shown that both HMnO2@CDDP and HMnO2 could significantly reduce the intracellular GSH level, indicating that it is the HMnO2 component that has the ability to deplete GSH in A549 cells.
[0076] (2) Detection of reactive oxygen levels
[0077] The intracellular reactive oxygen species ·OH were measured by confocal laser scanning microscopy (CLSM) and flow cytometry, and DCF was used as an evaluation index of ·OH level. The experimental method is as follows:
[0078] A549 cells were seeded in 6-well plates and cultured overnight at 37°C. Then, the cells were treated with CDDP, HMnO2, HMnO2@CDDP, and HMnO2@CDDP+NAC for 12 h, respectively. After washing the cells several times with PBS, 2',7'-dichlorodihydrofluorescein diacetate (DCFH-DA) solution (10 μM) was added and incubated with the cells for 30 min. After cellular uptake, DCFH-DA was deacetylated by cellular esterases to non-fluorescent compounds and subsequently oxidized by ROS to 2',7'-dichlorofluorescein (DCF). DCF is a fluorescent compound that can be detected by a fluorimeter, flow cytometer, or fluorescence microscope. Finally, the cells were observed using CLSM or the cells were collected as shown in Figure 2. Figure 4 As shown, the CDDP equivalent in the above CDDP, HMnO2@CDDP and HMnO2@CDDP+NAC is 10 μM; the Mn in HMnO2, HMnO2@CDDP and HMnO2@CDDP+NAC is 10 μM. 2+ The equivalent is 20 mg / ml; HMnO2@CDDP+NAC means that the anti-tumor nanodrug (HMnO2@CDDP) was pretreated with 1 mM acetylcysteine (NAC) for 1 hour.
[0079] Intracellular ROS can catalyze non-fluorescent DCFH-DA to generate fluorescent 2',7'-dichlorofluorescein (DCF), making it a ROS probe that can dynamically monitor ROS through fluorescence signals. Figure 5 As shown in the figure, almost no fluorescence was observed in A549 cells without any treatment (Control), indicating the basal ROS level in the cells. However, the ROS level of A549 cells treated with HMnO2 and HMnO2@CDDP was significantly upregulated, showing strong green fluorescence in the images taken by confocal fluorescence microscopy. Therefore, HMnO2 helps to increase the generation of ROS. In contrast, HMnO2@CDDP pretreated with NAC produced significantly lower ROS than cells incubated with HMnO2@CDDP alone due to the ROS scavenging ability of GSH, which further confirmed that the CDT toxicity of HMnO2@CDDP can be enhanced by consuming intracellular GSH.
[0080] (3) DNA damage detection
[0081] DNA damage was detected by CLSM. The experimental method is as follows:
[0082] A549 cells were seeded in 6-well plates and cultured overnight at 37°C. The cells were treated with CDDP, HMnO2, HMnO2@CDDP and HMnO2@CDDP+NAC for 12 hours, respectively, and the cells were washed with PBS and fixed with 4% paraformaldehyde. The cells were incubated with 1 mL of anti-γ-H2AX antibody (purchased from Biotech, Cat. No. C2035S) at 4°C overnight. Finally, 1 mL of the above fluorescently labeled antibody was used to stain the cells for 1 hour. When DNA damage occurs in the cells, the conserved amino acid sequence of H2AX is phosphorylated. H2AX is the earliest phosphorylated substrate and the most sensitive molecule in the cell to sense DNA damage. It is a protein marker for detecting DNA damage. Mounted with DAPI mounting medium, the CLSM images of the cells after fluorescently labeled antibody staining were observed under a confocal microscope as shown in the following figure. Figure 6 As shown, the CDDP equivalent in the above CDDP, HMnO2@CDDP and HMnO2@CDDP+NAC is 10 μM; the Mn in HMnO2, HMnO2@CDDP and HMnO2@CDDP+NAC is 10 μM. 2+ The equivalent is 20 mg / ml; HMnO2@CDDP+NAC means that the anti-tumor nanodrug (HMnO2@CDDP) was pretreated with 1 mM acetylcysteine (NAC) for 1 hour.
[0083] DNA damage was indirectly assessed by the phosphorylated H2AX Ser139 product (i.e., γ-H2AX) formed after DNA damage. Therefore, A549 cells were treated with CDDP alone, HMnO2, HMnO2@CDDP, and HMnO2@CDDP pretreated with NAC for 1 h. After treatment, cells were stained with γ-H2AX antibody and 4',6-diamidino-2-phenylindole (DAPI). Fluorescence expression was then observed by confocal fluorescence microscopy.
[0084] The results showed that compared with cells treated with CDDP or HMnO2 alone, the expression of γ-H2AX (a marker of DNA damage) induced by HMnO2@CDDP was significantly increased. However, excessive GSH in cancer cells usually prevents platinum-based drugs from binding to genomic DNA, thereby hindering the induced γ-H2AX formation. Figure 5 As shown in Figure 2, the GSH precursor N-acetylcysteine (NAC) (HMnO2@CDDP+NAC) used to pretreat A549 cells did significantly reduce the level of γ-H2AX formation, indicating that GSH has a negative impact on the chemotherapeutic effect of platinum-based drugs. These results confirm that Mn 2+ The components enhance the anticancer effects of platinum-based drugs by depleting intracellular GSH.
[0085] (5) Distribution of anti-tumor nanodrug HMnO2@CDDP in animals
[0086] The targeted modified HMnO2@CDDP nanodrug particles were labeled with Cy5.5 dye and Cy5.5 dye, respectively, and injected into A549 tumor-bearing nude mice through the tail vein. After 48 hours, the mice were killed, and the heart, liver, spleen, lung, kidney, and tumor were removed. In vitro fluorescence imaging was performed using a small animal in vivo imaging system. The results are shown in the figure. Figure 7 As shown, the fluorescence intensity in the tumor of the targeted modification group was significantly enhanced, showing a good tumor targeting effect.
[0087] From the above experimental results, we can see that HMnO2 can react with GSH to generate Mn due to its peroxidase-like catalytic ability. 2+ , then Mn 2+ In CO2 / HCO3 - With the assistance of HMnO2@CDDP, H2O2 is converted into ·OH through a Fenton-like reaction. HMnO2@CDDP depletes GSH in cancer cells in the tumor microenvironment, thereby amplifying the DNA damage caused by the chemotherapy drug CDDP, enhancing its chemotherapeutic efficacy, reducing GSH's protection against ROS and enhancing the effect of CDT, and ultimately leading to apoptosis of cancer cells. In addition, Mn 2+ It can be used for T1-weighted magnetic resonance imaging (MRI) in cancer theranostics.
Claims
1. A method for preparing a hollow drug-loaded nanozyme, It is characterized in that The preparation method comprises the following steps: S1: Adding manganese source to SiO 2 The nanoparticles are uniformly dispersed in an aqueous suspension to form a mixed solution, polyallylamine hydrochloride is added to the mixed solution, and MnO is obtained by a light-protected reaction. 2 Encapsulated SiO 2 of nanoparticles; The polyallylamine hydrochloride is added to the mixed solution in the form of an aqueous solution thereof, wherein the concentration of the polyallylamine hydrochloride aqueous solution is 10 to 50 M; S2: The MnO 2 Encapsulated SiO 2 Nanoparticles added with Na 2 CO 3 In aqueous solution, the SiO in the nanoparticles is removed by etching reaction at 60℃~85℃ 2 , to obtain MnO with a hollow interior 2 Nanoparticles; The Na 2 CO 3 The molar concentration of the aqueous solution is 0.5 to 4M.
2. The method for preparing the hollow drug-loaded nanozyme according to claim 1, It is characterized in that In step S1, the manganese source is KMnO 4 or MnSO 4 , the SiO 2 The nanoparticles are prepared by hydrolyzing ethyl orthosilicate in ethanol via ammonia catalysis. 3.An anti-tumor nanomedicine, It is characterized in that The anti-tumor nano drug is prepared by loading cisplatin in a hollow drug-loaded nano enzyme, and the hollow drug-loaded nano enzyme is prepared by the preparation method according to claim 1 or 2, and the hollow drug-loaded nano enzyme is a MnO 2 Nanoparticles, the MnO 2 The particle size of the nanoparticles is 170 to 230 nm.
4. The anti-tumor nano drug according to claim 3, It is characterized in that The tumors include ovarian cancer, prostate cancer, testicular cancer, lung cancer, nasopharyngeal cancer, esophageal cancer, malignant lymphoma, head and neck squamous cell carcinoma, thyroid cancer and osteogenic sarcoma.
5. A method for preparing the anti-tumor nano drug according to claim 3, It is characterized in that The preparation method comprises the following steps: adding the hollow drug-loaded nanozyme according to claim 1 into a cisplatin aqueous solution, and reacting in the dark to form MnO 2 The nano drug loaded with cisplatin on the nanoparticles is the anti-tumor nano drug.
6. The method for preparing the anti-tumor nano drug according to claim 5, It is characterized in that The hollow drug-loaded nanozyme is dispersed in water to form a dispersion with a concentration of 1 to 5 mg / mL, and the dispersion is added to a cisplatin aqueous solution to form a mixed solution, wherein the concentration of the cisplatin aqueous solution is 0.1 to 0.5 mg / mL, and the mass ratio of the hollow drug-loaded nanozyme to cisplatin in the mixed solution is 0.2:1.
